Puma Biotechnology remains undervalued despite steady neratinib sales and a promising, though early-stage, pipeline. Neratinib's combination with trastuzumab deruxtecan shows intriguing signals, ...
The biotechnology industry has long been characterized by astronomical development costs and lengthy timelines that can stretch into decades. Traditional drug development programs routinely require ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results